Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.

Enan ET, El-Hawary AK, El-Tantawy DA, Abu-Hashim MM, Helal NM.

Ann Diagn Pathol. 2013 Dec;17(6):490-3. doi: 10.1016/j.anndiagpath.2013.08.001. Epub 2013 Sep 6.

PMID:
24012547
2.

Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.

Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG.

Am J Surg Pathol. 2008 Mar;32(3):433-44. doi: 10.1097/PAS.0b013e318158142f.

PMID:
18300806
4.

Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.

Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, Huang Y, Li J, Wang Y, Gao Y, Han T, Du Z.

Am J Clin Pathol. 2012 Jun;137(6):937-45. doi: 10.1309/AJCP0KZZ5DSIGMNY.

PMID:
22586053
5.

Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.

McKnight R, Nassar A, Cohen C, Siddiqui MT.

Cancer Cytopathol. 2012 Aug 25;120(4):223-9. doi: 10.1002/cncy.21184. Epub 2012 Feb 1.

6.

Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.

Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, Evans M.

Cancer. 2007 Oct 25;111(5):316-22.

7.

A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.

Swanson BJ, Yearsley MM, Marsh W, Frankel WL.

Arch Pathol Lab Med. 2015 Apr;139(4):537-42. doi: 10.5858/arpa.2013-0645-OA.

PMID:
25822763
8.

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.

Wachter DL, Kristiansen G, Soll C, Hellerbrand C, Breuhahn K, Fritzsche F, Agaimy A, Hartmann A, Riener MO.

Histopathology. 2012 Jan;60(2):278-86. doi: 10.1111/j.1365-2559.2011.04091.x.

PMID:
22211286
9.

Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?

de Boer WB, Segal A, Frost FA, Sterrett GF.

Cancer. 2000 Oct 25;90(5):273-8.

PMID:
11038423
10.

Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.

Shafizadeh N, Ferrell LD, Kakar S.

Mod Pathol. 2008 Aug;21(8):1011-8. doi: 10.1038/modpathol.2008.85. Epub 2008 Jun 6.

11.

Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.

Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, Wu W, Sai WL, Yang JL, Zhang HJ.

Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):289-94.

PMID:
21669573
12.

Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.

Ibrahim TR, Abdel-Raouf SM.

Pathol Oncol Res. 2015 Apr;21(2):379-87. doi: 10.1007/s12253-014-9830-6. Epub 2014 Aug 10.

PMID:
25108409
13.

Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.

Tátrai P, Somorácz A, Batmunkh E, Schirmacher P, Kiss A, Schaff Z, Nagy P, Kovalszky I.

Am J Surg Pathol. 2009 Jun;33(6):874-85. doi: 10.1097/PAS.0b013e318194b3ea.

PMID:
19194276
14.

Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.

Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ.

Arch Pathol Lab Med. 2008 Nov;132(11):1723-8. doi: 10.1043/1543-2165-132.11.1723.

PMID:
18976006
15.

Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma.

Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, Zhang C.

J Histochem Cytochem. 2013 Sep;61(9):639-48. doi: 10.1369/0022155413492771. Epub 2013 May 16.

16.

Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.

Ligato S, Mandich D, Cartun RW.

Mod Pathol. 2008 May;21(5):626-31. doi: 10.1038/modpathol.2008.26. Epub 2008 Feb 8.

17.

Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.

Witjes CD, ten Kate FJ, Verhoef C, de Man RA, IJzermans JN.

J Clin Pathol. 2013 Aug;66(8):687-91. doi: 10.1136/jclinpath-2012-201156. Epub 2013 Apr 12.

PMID:
23585667
18.

[Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].

Bian YZ, Yao DF, Zhang CG, Li SS, Wu W, Dong ZZ, Qiu LW, Yu DD.

Zhonghua Gan Zang Bing Za Zhi. 2011 Apr;19(4):260-5. doi: 10.3760/cma.j.issn.1007-3418.2011.04.008. Chinese.

PMID:
21586223
19.

Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.

Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):170-6. doi: 10.1097/PAI.0b013e31825d527f.

PMID:
22914605
20.

Fibrolamellar hepatocellular carcinoma: an immunohistochemical comparison with conventional hepatocellular carcinoma.

Abdul-Al HM, Wang G, Makhlouf HR, Goodman ZD.

Int J Surg Pathol. 2010 Oct;18(5):313-8. doi: 10.1177/1066896910364229. Epub 2010 May 5.

PMID:
20444731

Supplemental Content

Support Center